George Hanna, MD
Interventional Cardiology · Bay City, TXNPI 1124027669
Payments from drug & device makers
Across 337 payments — averaging $122.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$34K
- Biotronik Inc.$3K
- Amarin Pharma, Inc.$706
- Amgen$606
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$462
- Sanofi-aventis U.S. LLC$458
- plus $3K from 26 others
What the payments were for
- Consulting fees$29,53871%
- Speaking & faculty fees$2,4006%
- Travel & lodging$1,8194%
- Food & beverage$7,59718%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 83 | $34,016 |
| Biotronik Inc. | 9 | $2,697 |
| Amarin Pharma, Inc. | 36 | $706 |
| Amgen | 32 | $606 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $462 |
| Sanofi-aventis U.S. LLC | 23 | $458 |
| Novartis | 27 | $441 |
| Cardiva Medical, Inc. | 17 | $328 |
| Merck | 15 | $248 |
| Johnson & Johnson | 10 | $213 |
| Pfizer | 8 | $154 |
| E.r. Squibb & Sons, L.L.C. | 8 | $138 |
| Heartflow, Inc. | 3 | $121 |
| Kowa Pharmaceuticals America, Inc. | 6 | $92 |
| Boston Scientific | 4 | $89 |
| Lexicon Pharmaceuticals, Inc. | 4 | $81 |
| Actelion Pharmaceuticals US, Inc. | 1 | $80 |
| Boehringer Ingelheim | 3 | $68 |
| Scpharmaceuticals Inc. | 3 | $67 |
| Penumbra, Inc. | 1 | $63 |
| Edwards Lifesciences | 1 | $50 |
| Shockwave Medical, Inc | 2 | $50 |
| Biosense Webster, Inc. | 2 | $44 |
| AstraZeneca | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Abiomed | 1 | $26 |
| Medtronic | 1 | $18 |
| Biomerieux Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Infobionic, Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assurity Pacemaker$10,449
- Accent Pacemaker$9,102
- Confirm Rx$6,149
- Fortify Assura, Ellipse ICD$4,378
- Allure Quadra RF CRT Pacemaker$2,982
- Merlin Connectivity and Remote$274
- PRALUENT$125
- Edora 8 DR-T$110
- BioMonitor$110
- Acticor 7 VR-T DX$110
- Rivacor 7 DR-T$110
How this compares
$41,447 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 787 | $847,209 |
| EntrestoSacubitril/Valsartan | 386 | $469,440 |
| XareltoRivaroxaban | 272 | $291,837 |
| Repatha SureclickEvolocumab | 154 | $162,030 |
| MultaqDronedarone Hcl | 39 | $41,812 |
| BrilintaTicagrelor | 47 | $36,068 |
| FarxigaDapagliflozin Propanediol | 34 | $32,176 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 75 | $26,816 |
| JardianceEmpagliflozin | 13 | $20,820 |
| Praluent PenAlirocumab | 20 | $16,626 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 1,330 | $15,792 |
| Ranolazine ErRanolazine | 93 | $15,321 |
| Nebivolol Hcl | 235 | $14,265 |
| ClopidogrelClopidogrel Bisulfate | 1,163 | $12,825 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 60 | $12,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $154 | $847,209787 claims |
| NovartisEntresto | $441 | $469,440386 claims |
| Johnson & JohnsonXarelto | $213 | $291,837272 claims |
| AstraZenecaBrilinta, Farxiga | $38 | $68,24481 claims |
| Sanofi-aventis U.S. LLCMultaq | $458 | $41,81239 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $14 | $33,15486 claims |
| Boehringer IngelheimJardiance | $68 | $20,82013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $6 | $7,75811 claims |
| Esperion Therapeutics, Inc.Nexletol | $16 | $4,37512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Bay City
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.